We compared antibody levels following separate but simultaneous administration of diphtheria and tetanus toxoids with acellular pertussis vaccine (DTaP) containing pertussis toxoid, filamentous hemagglutinin, and pertactin (PRN); hepatitis B vaccine; and Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate; PRP) vaccine conjugated to tetanus toxoid (PRP-T) with those following administration of a combination of a DTaP -hepatitis B vaccine -PRP-T to infants at 2, 4, and 6 months of age. The antibody response to a booster dose of PRP conjugate vaccine (CRM 197 -OS) in infants with low (õ1 mg/mL) or undetectable (õ0.10 mg/mL) postpriming levels of antibody to PRP was also studied. Antibody levels were quantitated before and after dose 3 by enzyme-linked immunosorbent assay, radioimmunoassay, or neutralization assay. Seroresponse rates were not different between the two vaccine groups except for rates of response to PRP. There was a trend that levels of antibody to all the antigens included in the combination vaccine were lower than those of antibody to antigens in separate vaccines; for levels of antibody to diphtheria toxoid (P Å .001), PRN (P õ .0001), and PRP (P õ .0001), the differences were significant. Despite low or undetectable postpriming levels of antibody to PRP, high-titered (geometric mean concentration, 9.02 mg/mL; range, 1.0 -81.5 mg/mL), immunoglobulin G -predominant antibody to PRP was produced following a booster dose of CRM 197 -OS, a finding consistent with a memory response.
Administration of Combined Diphtheria and Tetanus Toxoids and Pertussis
We compared antibody levels following separate but simultaneous administration of diphtheria and tetanus toxoids with acellular pertussis vaccine (DTaP) containing pertussis toxoid, filamentous hemagglutinin, and pertactin (PRN); hepatitis B vaccine; and Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate; PRP) vaccine conjugated to tetanus toxoid (PRP-T) with those following administration of a combination of a DTaP -hepatitis B vaccine -PRP-T to infants at 2, 4, and 6 months of age. The antibody response to a booster dose of PRP conjugate vaccine (CRM 197 -OS) in infants with low (õ1 mg/mL) or undetectable (õ0.10 mg/mL) postpriming levels of antibody to PRP was also studied. Antibody levels were quantitated before and after dose 3 by enzyme-linked immunosorbent assay, radioimmunoassay, or neutralization assay. Seroresponse rates were not different between the two vaccine groups except for rates of response to PRP. There was a trend that levels of antibody to all the antigens included in the combination vaccine were lower than those of antibody to antigens in separate vaccines; for levels of antibody to diphtheria toxoid (P Å .001), PRN (P õ .0001), and PRP (P õ .0001), the differences were significant. Despite low or undetectable postpriming levels of antibody to PRP, high-titered (geometric mean concentration, 9.02 mg/mL; range, 1.0 -81.5 mg/mL), immunoglobulin G -predominant antibody to PRP was produced following a booster dose of CRM 197 -OS, a finding consistent with a memory response.
Combination vaccines are needed to simplify the childhood sure to PRP [8 -12] . This priming may occur in infants with low or even undetectable responses of serum antibody to PRP immunization schedule. In recent trials, diphtheria and tetanus toxoids with acellular pertussis vaccine (DTaP) formulations after PRP conjugate vaccination. The response of infants to a booster dose of PRP vaccine can be taken to mimic contact combined with Haemophilus influenzae type b (Hib) conjugate vaccines (with or without hepatitis B vaccines) administered with invading Hib organisms with a PRP capsule on their surface and indicate the expected response to infection [13 -to infants at 2, 4, and 6 months of age as a primary series have produced lower levels of antibody to the Hib polysaccharide 15]. Here, we compared antibody responses after administration of a combination of DTaP -hepatitis B vaccine -PRP vac-(polyribosylribitol phosphate; PRP) than simultaneous but separate injections [1 -5] . This appears to be a general phenomecine conjugated to tetanus toxoid (PRP-T) with those after separate but simultaneous administration of DTaP, hepatitis B non involving different DTaP formulations and different Hib conjugate vaccines from several manufacturers. The biological vaccine, and PRP-T to infants; we also characterized the antibody response to PRP conjugate revaccination in those infants significance of the diminished levels of antibody to PRP are uncertain [5 -7] . The immune response to the components in with low (õ1.0 mg/mL) or undetectable (õ0.10 mg/mL) postpriming levels of antibody to PRP. the DTaP formulations has been described as similar following combination or separate injections [2 -5] .
As a separate injection, Hib conjugate vaccines are known Study Design to prime infants for memory responses to a subsequent expo-before vaccination at 2 months of age and 1 month after the third vaccination at 7 months of age.
ELISA methods for determination of PTox, FHA, and PRN were adopted from protocols provided by the U.S. Food and Drug Administration (courtesy of Dr. Bruce Meade, Bethesda, PRP Conjugate Revaccination MD) [16] . All plated volumes were 100 mL. Polystyrene 96-Infants in group 1 from Rochester (n Å 43), with postpriming well microtiter plates of medium binding capacity (Dynatech levels of antibody to PRP of õ1.0 mg/mL received a booster Immulon I, Chantilly, VA) were coated with the following dose of PRP conjugate vaccine (CRM 197 -OS) at 9 -13 months optimized concentrations of purified antigen: PTox, 0.75 of age. Serum samples were obtained from these infants before mg/mL; FHA, 1 mg/mL; and PRN, 2 mg/mL in carbonate buffer the booster dose was administered and 1 month after the booster (0.05 M sodium carbonate, pH 9.6). PTox-and PRN-coated dose was administered. [Sigma] in 1 M Tris, pH 9.8, containing 1 mM MgCl 2 ) was diphtheria and tetanus toxoids manufactured by Chiron Behring added to each well. After a 60-minute incubation at room temGmbH (Markburg, Germany) and was formulated at Smithperature, 50 mL of 3 N NaOH was added, and the plates were Kline Beecham Biologicals with the same lot of acellular read at dual wavelengths (absorbance, 405 and 630 nm). pertussis tricomponent vaccine used for group 1. Hepatitis B For each ELISA, a minimum level of detection was defined. vaccine and PRP-T were from the same lots and vaccine manuThis value was defined as the minimum amount of antibody, facturers that were used for group 1. in units, that had to be present for the serum to have at least When combined with the same acellular pertussis vaccine one point within the linear range of the reference serum doseproduct, different diphtheria and tetanus toxoids were included response curve. This value was estimated to be 2 ELISA units in the vaccines given to group 1 infants vs. group 2 infants to (EU)/mL for PTox, 3 EU/mL for FHA, and 4 EU/mL for PRN. bridge safety and serology results for the two manufacturing
The coefficients of variation for the assays were 21% for PTox sources. Oral poliovirus vaccine was administered to all vaccin-(180 determinations), 13% for FHA (165 determinations), and ees in both groups concurrently at 2, 4, and 6 months of age.
14% for PRN (175 determinations). All vaccines were from a single lot.
Booster Dose of Vaccine ELISAs for Diphtheria and Tetanus Toxoids
The vaccine used for booster doses was CRM 197 -OS, which ELISAs for diphtheria and tetanus toxoids were performed consisted of a mutant variant of diphtheria toxin conjugated by methods similar to those described by Melville-Smith and to PRP oligosaccharide (Lederle-Praxis Biologicals, WyethBalfour [17] and Melville-Smith et al. [18] . Ninety-six-well Lederle, Rochester, NY).
microtiter plates of medium binding capacity (Dynatech Immulon III, Chantilly, VA) were coated with 100 mL of diphtheria and tetanus toxoids (concentrations, 10 and 1 Lf unit/mL, reAssay Methods spectively) in sterile PBS (0.01 M sodium phosphate/0.14 M sodium chloride, pH 7.4) at 37ЊC for 16 -20 hours. (AntigenAll assays were performed at the University of Rochester (Rochester, NY) in the laboratory of the investigators. coated plates can be stored at 4ЊC for up to 1 month.) Coated / 9c40$$de55 11-11-97 17:16:52 cidal UC: CID plates were washed with wash solution (PBS/0.1% Tween 20) IU/mL; hepatitis B surface antigens, mIU/mL; PTox, FHA, and PRN, EU/mL; and PRP, mg/mL. and incubated for 1 hour at room temperature; twofold serial dilutions (initial dilution, 1:50) of serum samples in PBS/0.05% Tween 20 were tested. After washing, the plates were incubated Statistical Analysis for 1 hour at room temperature with 100 mL of alkaline phosphatase -labeled goat antibody to human IgG in PBS/0.05% For statistical calculations, serum samples in which the antiTween 20 (Tago, Camarillo, CA). The optimal dilution of the body concentration was less than the minimum detectable level antibody to human IgG to be used was determined empirically were assigned a value equal to one-half of that level. Geometric for each assay.
mean concentrations (GMCs) of antibody were compared by After incubation, the plates were washed, and 100 mL of means of the Student's t test. Differences in attaining defined substrate solution (1 mg of p-nitrophenyl phosphate/mL in antibody levels between vaccine groups were compared by 1 M diethanolamine, pH 9.8, containing 1 mM MgCl 2 ) was using the x 2 test. added to each well. Plates were incubated for 1 hour at room temperature, and then 50 mL of 3 N NaOH solution was added to each well; the plates were assayed for absorbance at waveResults lengths of 405 nm and 630 nm. The minimum level of detection for diphtheria and tetanus toxins was estimated to be 0.05
Two hundred fifty-one children received the combination of DTaP -hepatitis B vaccine -PRP-T (group 1), and 80 children IU/mL. The coefficients of variation for the assays were 15% for diphtheria toxoid (370 determinations) and 11% for tetanus received separate injections of DTaP, hepatitis B vaccine, and PRP-T (group 2). Preimmunization antibody levels were simitoxoid (480 determinations). lar in the two cohorts for the primary series (data not shown). Levels of antibody to tetanus toxoid, hepatitis B surface anti-
PRP ELISA
gen, PTox, and FHA were not significantly different in group 1 than in group 2 following primary vaccination (table 1) . Antibody to PRP was quantitated by ELISA, as described by Phipps et al. [19] , with use of Hib oligosaccharide -human Levels of antibody to diphtheria toxoid (P Å .001), PRN (P õ .0001), and PRP (P õ .0001) were lower in group 1 than serum albumin conjugate (lower limit of detection, 0.10 mg antibody/mL). The coefficient of variation for the assay was in group 2 (table 1). The percentage of infants with a presumed protective level of §0.1 IU/mL for diphtheria toxoid [22] was 12% (420 determinations). The secondary antibody in the ELISA was alkaline phosphatase -labeled goat antibody to hu-100% in both vaccine groups, and the rate of seroresponse to PRN was comparable (92.8% vs. 95.9%, respectively) between man Ig (IgG, IgA, and IgM), goat antibody to human IgG, or goat antibody to human IgM (Tago). group 1 and group 2. However, the percentage of infants achieving a level of antibody to PRP of §0.15 mg/mL and §1.0 mg/mL was significantly lower in group 1 than in group Hepatitis B Surface Antigen RIA 2 (P Å .007 and P õ .0001, respectively). The postpriming, prebooster dose, and 1-month postbooster Antibody to hepatitis B surface antigen was measured by RIA that was performed as described in a commercial kit dose levels of antibody to PRP in the 43 group 1 children from Rochester who had low or undetectable levels of antibody to (AUSUB kit, Abbott Laboratories, North Chicago, IL). The lower limit of detection was 10 mIU/mL, and the coefficient PRP after administration of DTaP -hepatitis B vaccine -PRP-T are shown in table 2. From postpriming to the prebooster of variation was 18% (60 determinations).
dose, all but two of the 43 children had similar or diminished levels of antibody to PRP (table 2), a finding suggesting that
Reference Sera and Antibody Quantitation exposure to wild-type Hib or cross-reacting bacterial antigens did not occur. All of the vaccinees had a rise in the level of Reference sera for diphtheria and tetanus toxoids were calibrated against an international (World Health Organization) antibody to PRP following the booster dose of CRM 197 -OS (table 2) . Following the booster dose, the GMC rose to 9.02 standard. Reference sera for PTox, FHA, and PRN were internal references calibrated against the U.S. Food and Drug Admg/mL, and the levels of antibody to PRP were §0.15 mg/mL in 100% of the children and §1.0 mg/mL in 100% of the ministration reference lot number 3 (PTox and FHA) and lot number 4 (PRN). Reference sera for PRP were the CBER children who did not have antibodies previously (table 3) . We also evaluated the isotype of antibody to PRP in a subset standard lot 1983 which contained 70 mg/mL.
The NOTE. Group 1 Å infants who received combination of DTaP -hepatitis B vaccine -PRP-T at 2, 4, and 6 months of age; group 2 Å infants who received separate injections of DTaP, hepatitis B vaccine, and PRP-T at 2, 4, and 6 months of age. Abbreviations: DTaP Å diphtheria and tetanus toxoids with acellular pertussis vaccine; EU Å ELISA unit; FHA Å filamentous hemagglutinin; GMC Å geometric mean concentration; HB s Ag Å hepatitis B surface antigen; n Å no. of assayed serum samples that differ for different antigens because of serum quantities; PRN Å pertactin; PRP Å polyribosylribitolphosphate; PRP-T Å PRP vaccine conjugated to tetanus toxoid; PTox Å pertussis toxin.
* P Å .001. † Percentage of samples with indicated antibody level. ‡ P Å .30. § P Å .14.
x No. of samples with seroresponse/total no. tested (%). Seroresponse definition: if initially seronegative, a postvaccination titer of §5 EU/mL; if initially seropositive, there was at least maintenance of the prevaccination titer. There were only 237 and 73 samples for groups 1 and 2, respectively, because paired serum samples were not always available.
# P Å . (CRM 197 ) than the carrier used in the primary series of vaccinations (tetanus toxoid) in both vaccine groups had levels of antibody to diphtheria toxoid after dose 3 of ú0.1 IU/mL, and 92.8% achieved seroreto minimize the effect of carrier-induced T helper cells. In addition, CRM 197 -OS does not give rise to high levels of antisponses to PRN after dose 3. Therefore, the differences in the observed levels of antibody to diphtheria toxoid are of uncertain body to PRP after a single injection [27 -29] . Comparisons of the levels of antibody to PRP in CRM 197 -OS-vaccinated chilclinical importance, since all patients achieved a level of antidren from our study with those in historical controls would not body associated with protection against disease [22] . Because be appropriate. The only historical antibody data available on a protective level of antibody to PRN following administration administration of a single dose of CRM 197 -OS to 9-to 13-of DTaP has not been established, the clinical importance of month-old children involved prelicensure CRM 197 -OS, and the the observed differences in GMCs between the study groups prelicensure product induces antibody to PRP at different levels may be of importance but cannot be assessed at this time.
and with different characteristics than does the licensed GMCs of antibody to PRP were lower in group 1 than in CRM 197 -OS that we used [30]; infants receiving postlicensure group 2 (P õ .0001), and the presumed protection level of CRM 197 -OS at 5 to 6 months of age achieve a GMC of antibody §0.15 mg/mL was achieved in 81.3% of infants in group 1 vs.
to PRP of 1.30 mg/mL (95% CI Å 0.29 -5.71) [27] . 93.8% in group 2 (P Å .007).
Use of unconjugated PRP vaccine as a booster dose would The Hib capsular polysaccharide PRP is a T lymphocytehave been of interest because this vaccine might have better independent antigen [8 -12] . Conjugation to a protein carrier reflected natural exposure to Hib [13 -15] . Examination of the supplies T cell epitopes [11] . Presentation of such epitopes to kinetics of the response of antibody to PRP with a booster dose CD4 / T helper cells by PRP-specific B cells leads to activation also might have been helpful, since primed infants might show and clonal expansion of both carrier-specific T cells and polya more rapid increase in antibody levels than unprimed infants. saccharide-specific B cells [11] . This occurrence explains the Using the same combination of DTaP -hepatitis B vaccineability of PRP conjugate vaccines to induce higher antibody PRP-T that we used but in a different schedule for the primary responses than unconjugated PRP vaccines as well as the ability series, Zepp et al. [5 -7] . Pure PRP vaccine does not tion of adjuvants to combination vaccines may result in some prime for immunologic memory or a booster response, which normally adjuvanted components of the vaccine being adsorbed is in contrast to PRP conjugate products. For these reasons, we to the adjuvant or other normally adsorbed components being investigated whether reconstituting PRP-T with liquid DTaPdisplaced from the adjuvant. An effect of the protein carrier hepatitis B vaccine for administration as one injection intercould be hypothesized as a mechanism for reduced responses of feres with the induction of immunologic memory; to do this antibody to PRP through carrier-induced epitope suppression. we observed the immune response to a booster dose of CRM 197 -Further, with combination vaccines, antigen competition might OS 3 to 7 months later.
occur at the germinal centers of regional lymph nodes. A study The expected response in primed subjects should be a rapid where simultaneous injections of multiple vaccines in the same anamnestic response with high GMCs of antibody dominated extremity are compared with injections in different extremities by IgG [11] . We found evidence that immunologic memory is of infants could assess this possibility. induced and that a booster IgG response occurs in infants Serological assays that correlate with efficacy will need to primed with PRP-T administered in combination with DTaPbe used as surrogates for efficacy trials. Combined vaccines hepatitis B vaccine as a single injection. Even in infants with with some variations in immunogenicity may need to be aclow (õ1.0 mg/mL) and undetectable (õ0.10 mg/mL) postprimcepted, as long as protective efficacy is preserved, to meet the ing levels of antibody to PRP, high-titered IgG-predominant goals of the Children's Vaccine Initiative: (1) to reduce the booster responses were observed. Thus, the combination of number of contacts required to fully immunize the child, and DTaP -hepatitis B vaccine -PRP-T appears to prime the infant (2) to reduce the number of immunizations administered at immune system for secondary-type responses of antibody to each visit. PRP, which is typical for separate injections of Hib conjugate vaccine.
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